Information Provided By: 
Fly News Breaks for August 23, 2018
AKBA, KERX
Aug 23, 2018 | 07:30 EDT
H.C. Wainwright analyst Jason Kolbert believes the merger between Keryx Biopharmaceuticals (KERX) and Akebia Therapeutics (AKBA) remains on track. According to the Federal Trade Commission website, the status of the merger application now shows "granted," Kolbert tells investors in a research note. The analyst says that while he did not expect FTC clearance to be an issue, "it's good to see it granted." He keeps a Buy rating on Keryx with a $9 price target.
News For KERX;AKBA From the Last 2 Days
There are no results for your query KERX;AKBA
